Cargando…
P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)
Autores principales: | Carlo-Stella, Carmelo, Lahn, Michael, Hammett, Tracey, van der Veen, Lars, Zorrilla, Rebeca, Pickering, Catherine, Santoro, Armando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431057/ http://dx.doi.org/10.1097/01.HS9.0000971352.17216.e2 |
Ejemplares similares
-
P1116: SAFETY, PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD) AND ACTIVITY OF THE HIGHLY SELECTIVE PHOSPHOINOSITIDE 3-KINASE INHIBITOR DELTA (PI3KΔ) INHIBITOR IOA-244 IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
por: Carlostella, C., et al.
Publicado: (2022) -
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib
por: van der Veen, Lars, et al.
Publicado: (2023) -
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
por: Johnson, Zoë, et al.
Publicado: (2023) -
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
por: Deken, M.A., et al.
Publicado: (2023) -
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
por: Centonze, Matteo, et al.
Publicado: (2023)